{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T13:22:27Z","timestamp":1765545747910,"version":"3.40.3"},"reference-count":85,"publisher":"Walter de Gruyter GmbH","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,6,1]]},"abstract":"<jats:title>Immunomodulatory effects of anti-estrogenic drugs<\/jats:title><jats:p>There are substantial experimental, epidemiological and clinical evidences that show that breast cancer pathology is influenced by endogenous estrogens. This knowledge is the foundation upon which endocrine deprivation therapy has been developed as a major modality for the management of breast cancer. Tamoxifen, which functions as a competitive partial agonist-inhibitor of estrogen at its receptor, has been widely used for more than three decades for adjuvant endocrine treatment in breast cancer. Currently, other effective drugs for endocrine therapy include raloxifene, different aromatase inhibitors (particularly third-generation agents) and luteinizing hormone-releasing hormone agonists. In recent years, a growing body of evidence suggests that these drugs can also act as immune modulators by altering the function of various leukocytes and the release of different cytokines. Moreover, there is evidence that anti-estrogens may prove to be beneficial in the treatment or prevention of some autoimmune diseases due to their effects on immune function. However, their immunopharmacological aspects in the present state of knowledge are not precisely comprehensible. Only a clear pathophysiological understanding could lead to an efficient strategy for breast cancer prevention and decrease in the mortality due to this disease.<\/jats:p>","DOI":"10.2478\/v10007-012-0012-3","type":"journal-article","created":{"date-parts":[[2012,6,29]],"date-time":"2012-06-29T14:49:11Z","timestamp":1340981351000},"page":"141-155","source":"Crossref","is-referenced-by-count":22,"title":["Immunomodulatory effects of anti-estrogenic drugs"],"prefix":"10.2478","volume":"62","author":[{"given":"Amitabha","family":"Ray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Ficek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"1","first-page":"13","article-title":"Estrogen and breast cancer","volume":"33","author":"A. Ray","year":"2003","journal-title":"ICMR Bull"},{"key":"2","first-page":"35","article-title":"Epidemiological risk factors for breast cancer - a review","volume":"8","author":"M. Okobia","year":"2005","journal-title":"Niger. J. Clin. Pract"},{"key":"3","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s12282-008-0062-z","article-title":"Intratumoral estrogen production in breast carcinoma: significance of aromatase","volume":"15","author":"T. Suzuki","year":"2008","journal-title":"Breast Cancer"},{"key":"4","first-page":"126","article-title":"Aromatase research and its clinical significance","volume":"61","author":"I. Czajka-Oraniec","year":"2010","journal-title":"Endokrynol. Pol"},{"key":"5","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S1471-4914(02)02282-7","article-title":"Selective estrogen receptor modulators (SERMs) and their roles in breast cancer prevention","volume":"8","author":"W. Park","year":"2002","journal-title":"Trends Mol. Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/S0140-6736(01)72384-7","article-title":"On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new treatment with illustrative cases","volume":"2","author":"G. Beatson","year":"1896","journal-title":"Lancet"},{"key":"7","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/S0093-7754(03)00305-1","article-title":"Oestrogens and breast cancer: biological considerations","volume":"47","author":"W. Miller","year":"1991","journal-title":"Br. Med. Bull"},{"key":"8","first-page":"1449","volume-title":"The Cancer Handbook","volume":"2","author":"V. Jordan","year":"2002"},{"issue":"14","key":"9","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0093-7754(03)00305-1","article-title":"Pharmacokinetics of third-generation aromatase inhibitors","volume":"30","author":"P. Lonning","year":"2003","journal-title":"Semin. Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2217\/whe.10.25","article-title":"Optimal adjuvant endocrine therapy for early breast cancer","volume":"6","author":"R. Stuart-Harris","year":"2010","journal-title":"Women's Health"},{"issue":"8","key":"11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgyn.2010.10.004","volume-title":"J. Gynecol. Obstet. Biol. Reprod","volume":"39","author":"T. Delozier","year":"2010"},{"key":"12","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.coph.2010.09.007","article-title":"The molecular mechanisms underlying the pharmacological actions of ER modulators: implications for new drug discovery in breast cancer","volume":"10","author":"D. McDonnell","year":"2010","journal-title":"Curr. Opin. Pharmacol"},{"key":"13","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/092986711794480177","article-title":"Endocrine therapy of breast cancer","volume":"18","author":"F. Lumachi","year":"2011","journal-title":"Curr. Med. Chem"},{"key":"14","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.2146\/ajhp070663","article-title":"Chemoprevention of breast cancer","volume":"65","author":"A. Thomsen","year":"2008","journal-title":"Am. J. Health Syst. Pharm"},{"key":"15","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2174\/157489211795328486","article-title":"Tamoxifen and its new derivatives in cancer research","volume":"6","author":"C. Rivera-Guevara","year":"2011","journal-title":"Recent Pat. Anticancer Drug Discov"},{"key":"16","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/978-0-387-78818-0_14","article-title":"Pharmacogenomics of endocrine therapy in breast cancer","volume":"630","author":"R. Weinshilboum","year":"2008","journal-title":"Adv. Exp. Med. Biol"},{"key":"17","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1373\/clinchem.2008.121756","article-title":"Pharmacogenomics of tamoxifen therapy","volume":"55","author":"H. Brauch","year":"2009","journal-title":"Clin. Chem"},{"key":"18","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0031-6997(24)01479-0","article-title":"Cellular and molecular pharmacology of antiestrogen action and resistance","volume":"53","author":"R. Clarke","year":"2001","journal-title":"Pharmacol. Rev"},{"key":"19","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1677\/erc.1.00776","article-title":"Mechanisms of tamoxifen resistance","volume":"11","author":"A. Ring","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"key":"20","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1158\/0008-5472.CAN-09-3292","article-title":"Antiestrogens induce transforming growth factor beta-mediated immunosuppression in breast cancer","volume":"70","author":"C. Joffroy","year":"2010","journal-title":"Cancer Res"},{"key":"21","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/BF01805743","article-title":"Influence of adjuvant tamoxifen on blood lymphocytes","volume":"12","author":"S. Rotstein","year":"1988","journal-title":"Breast Cancer Res. Treat"},{"key":"22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/BF01525437","article-title":"In vivo modulation of natural killer cell activity by tamoxifen in patients with bilateral primary breast cancer","volume":"37","author":"E. Robinson","year":"1993","journal-title":"Cancer Immunol. Immunother"},{"key":"23","first-page":"689","article-title":"Effect of tamoxifen on parameters of cell-mediated immunity in post-menopausal patients with breast carcinoma","volume":"113","author":"P. Mallmann","year":"1991","journal-title":"Zbl. Gynakol"},{"key":"24","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/BF00666482","article-title":"Natural killer cell activity, phagocytosis, and number of peripheral blood cells in breast cancer patients treated with tamoxifen","volume":"29","author":"J. Lukac","year":"1994","journal-title":"Breast Cancer Res. Treat"},{"key":"25","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s005200050245","article-title":"Interaction of tamoxifen with concurrent cytotoxic adjuvant treatment affects lymphocytes and lymphocyte subsets counts in breast cancer patients","volume":"7","author":"M. Sabbioni","year":"1999","journal-title":"Support. Care Cancer"},{"key":"26","first-page":"2027","article-title":"Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells","volume":"20","author":"E. Baral","year":"2000","journal-title":"Anticancer Res"},{"key":"27","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1002\/(SICI)1097-0215(19960807)","article-title":"Anti-estrogens enhance the therapeutic effect of lymphokine-activated killer cells on the P815 murine mastocytoma","volume":"67","author":"E. Baral","year":"1996","journal-title":"Int. J. Cancer"},{"key":"28","first-page":"3653","article-title":"Combination immunotherapy of the P815 murine mastocytoma with killer cells, IL-2 and anti-estrogens","volume":"17","author":"E. Baral","year":"1997","journal-title":"Anticancer Res"},{"key":"29","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00404-007-0521-3","article-title":"Effects of raloxifene and hormone replacement therapy on serum Th2 and Th3 type cytokine concentrations in healthy postmenopausal women: a randomised controlled trial","volume":"277","author":"S. Kumru","year":"2008","journal-title":"Arch. Gynecol. Obstet"},{"key":"30","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.3899\/jrheum.090911","article-title":"Raloxifene modulates estrogen-mediated B cell autoreactivity in NZB\/W F1 mice","volume":"37","author":"Y. Zhang","year":"2010","journal-title":"J. Rheumatol"},{"key":"31","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.4049\/jimmunol.175.4.2666","article-title":"The selective estrogen receptor modulators, tamoxifen and raloxifene, impair dendritic cell differentiation and activation","volume":"175","author":"G. Nalbandian","year":"2005","journal-title":"J. Immunol"},{"key":"32","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1177\/039463200601900410","article-title":"Estrogen receptor agonists and immune system in ovariectomized mice","volume":"19","author":"M. Garc\u00eda-P\u00e9rez","year":"2006","journal-title":"Int. J. Immunopathol. Pharmacol"},{"key":"33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1006\/cimm.2000.1719","article-title":"Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice","volume":"205","author":"M. Erlandsson","year":"2000","journal-title":"Cell. Immunol"},{"key":"34","first-page":"881","article-title":"Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens","volume":"29","author":"H. Masuoka","year":"2002","journal-title":"Jpn. J. Cancer. Res"},{"key":"35","first-page":"1849","article-title":"Antiestrogens affect both pathways of killer cell-mediated oncolysis","volume":"20","author":"S. Haeryfar","year":"2000","journal-title":"Anticancer Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1046\/j.1365-3083.1998.00388.x","article-title":"Antioestrogens enhance tumour necrosis factor receptor 2 (TNF-R2) expression and TNF-R2-mediated proliferation in activated T cells","volume":"48","author":"J. Komi","year":"1998","journal-title":"Scand. J. Immunol"},{"key":"37","first-page":"279","article-title":"Modulation of biological responses of normal human mononuclear cells by antiestrogens","volume":"13","author":"J. Teodorczyk-Injeyan","year":"1993","journal-title":"Anticancer Res"},{"key":"38","first-page":"215","article-title":"The effect of toremifene on the expression of some genes in human mononuclear cells","volume":"9","author":"J. Kellen","year":"1995","journal-title":"In Vivo"},{"key":"39","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1365-3083.1996.d01-85.x","article-title":"The effect of anti-oestrogens on cytokine production in vitro","volume":"44","author":"L. J\u00e4rvinen","year":"1996","journal-title":"Scand. J. Immunol"},{"key":"40","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1002\/pmic.201000720","article-title":"2-D gel electrophoresis-based proteomic analysis reveals that ormeloxifen induces G0-G1 growth arrest and ERK-mediated apoptosis in chronic myeloid leukemia cells K562","volume":"11","author":"P. Pal","year":"2011","journal-title":"Proteomics"},{"key":"41","first-page":"387","article-title":"Effect of centchroman on cellular and humoral immunity","volume":"51","author":"L. Thomas","year":"2007","journal-title":"Indian J. Physiol. Pharmacol"},{"key":"42","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/sj.bjc.6600785","article-title":"Inhibition of IL-6+ IL-6 soluble receptor-stimulated aromatase activity by the IL-6 antagonist, Sant 7, in breast tissue-derived fibroblasts","volume":"88","author":"A. Purohit","year":"2003","journal-title":"Br. J. Cancer"},{"key":"43","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1158\/1940-6207.CAPR-11-0110","article-title":"Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer","volume":"4","author":"P. Morris","year":"2011","journal-title":"Cancer Prev. Res"},{"key":"44","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/BF00199836","article-title":"Modulation of natural killer cell activity in stage I post-menopausal breast cancer patients on low-dose aminoglutethimide","volume":"24","author":"J. Berry","year":"1987","journal-title":"Cancer Immunol. Immunother"},{"key":"45","first-page":"637","article-title":"Evidence for the involvement of corticosterone in the ontogeny of the cellular immune apparatus of the mouse","volume":"35","author":"H. van Dijk","year":"1978","journal-title":"Immunology"},{"key":"46","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.etap.2003.08.003","article-title":"Aminoglutethimide-induced leukopenia in a mouse model: effects of metabolic and structural determinants","volume":"15","author":"M. Coleman","year":"2003","journal-title":"Environ. Toxicol. Pharmacol"},{"key":"47","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1095\/?biolreprod.103.017590","article-title":"Effects of prostaglandin F2alpha and progesterone on the ability of bovine luteal cells to stimulate T lymphocyte proliferation","volume":"69","author":"M. Cannon","year":"2003","journal-title":"Biol. Reprod"},{"key":"48","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.amjsurg.2005.06.013","article-title":"Aromatase inhibitors increase the sensitivity of human tumor cells to monocyte-mediated, antibody-dependent cellular cytotoxicity","volume":"190","author":"D. Braun","year":"2005","journal-title":"Am. J. Surg"},{"key":"49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/00024382-200014030-00019","article-title":"The aromatase inhibitor, 4-hydroxyandrostenedione, restores immune responses following trauma-hemorrhage in males and decreases mortality from subsequent sepsis","volume":"14","author":"C. Schneider","year":"2000","journal-title":"Shock"},{"key":"50","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1016\/S0020-7519(02)00130-3","article-title":"Inhibition of p-450 aromatase prevents feminisation and induces protection during cysticercosis","volume":"32","author":"J. Morales-Montor","year":"2002","journal-title":"Int. J. Parasitol"},{"key":"51","first-page":"1211","article-title":"Late phase II study of exemestane in postmenopausal patients with breast cancer resistant to anti-estrogenic agents","volume":"29","author":"T. Watanabe","year":"2002","journal-title":"Gan. To. Kagaku. Ryoho. (Cancer & Chemotherapy)"},{"key":"52","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s10549-010-0887-y","article-title":"Gene expression profiling and prediction of response to hormonal neoadjuvant treatment with anastrozole in surgically resectable breast cancer","volume":"121","author":"M. Mello-Grand","year":"2010","journal-title":"Breast Cancer Res. Treat"},{"key":"53","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12032-009-9191-2","article-title":"Mean platelet volume increase after tamoxifen, but not after anastrazole in adjuvant therapy of breast cancer","volume":"27","author":"B. Karag\u00f6z","year":"2010","journal-title":"Med. Oncol"},{"key":"54","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1158\/1078-0432.CCR-08-1507","article-title":"Immuno-modulation of FOXP3+ regulatory T cells by the aromatase inhibitor letrozole in breast cancer patients","volume":"15","author":"D. Generali","year":"2009","journal-title":"Clin. Cancer Res"},{"key":"55","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1097\/COC.0b013e3181cae782","article-title":"Immunological therapies can relieve aromatase inhibitor-reated joint symptoms in breast cancer survivors","volume":"33","author":"Q. Zhang","year":"2010","journal-title":"Am. J. Clin. Oncol"},{"key":"56","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.exger.2009.03.003","article-title":"Immoderate inhibition of estrogen by anastrozole enhances the severity of experimental polyarthritis","volume":"44","author":"J. Wang","year":"2009","journal-title":"Exp. Gerontol"},{"key":"57","first-page":"144","article-title":"The multiple applications of tamoxifen: an example pointing to SERM modulation being the aspirin of the 21st century","volume":"14","author":"M. Singh","year":"2008","journal-title":"Med. Sci. Monit"},{"key":"58","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood.V95.9.2875.009k12_2875_2882","article-title":"Nonsteroidal anti-estrogens inhibit the functional differentiation of human monocyte-derived dendritic cells","volume":"95","author":"J. Komi","year":"2000","journal-title":"Blood"},{"key":"59","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1093\/rheumatology\/40.2.185","article-title":"Non-steroidal anti-oestrogens inhibit the differentiation of synovial macrophages into dendritic cells","volume":"40","author":"J. Komi","year":"2001","journal-title":"Rheumatology"},{"key":"60","doi-asserted-by":"crossref","first-page":"3076","DOI":"10.2174\/092986709788803042","article-title":"The effects of tamoxifen on immunity","volume":"16","author":"S. Behjati","year":"2009","journal-title":"Curr. Med. Chem"},{"key":"61","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1002\/glia.20805","article-title":"Treatment with selective estrogen receptor modulators regulates myelin specific T-cells and suppresses experimental autoimmune encephalomyelitis","volume":"57","author":"B. Bebo, Jr","year":"2009","journal-title":"Glia"},{"key":"62","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/archderm.142.1.70","article-title":"Improvement in dermatomyositis rash associated with the use of antiestrogen medication","volume":"142","author":"D. Sereda","year":"2006","journal-title":"Arch. Dermatol"},{"key":"63","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1111\/j.1365-2222.2010.03472.x","article-title":"Tamoxifen counteracts the allergic immune response and improves allergen-induced dermatitis in mice","volume":"40","author":"M. Babina","year":"2010","journal-title":"Clin. Exp. Allergy"},{"key":"64","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1046\/j.1365-2567.2000.00998.x","article-title":"Tamoxifen alleviates disease severity and decreases double negative T cells in autoimmune MRL-lpr\/lpr mice","volume":"100","author":"W. Wu","year":"2000","journal-title":"Immunology"},{"key":"65","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1046\/j.1365-3083.2000.00789.x","article-title":"Tamoxifen decreases renal inflammation and alleviates disease severity in autoimmune NZB\/W F1 mice","volume":"52","author":"W. Wu","year":"2000","journal-title":"Scand. J. Immunol"},{"key":"66","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1136\/ard.62.4.341","article-title":"Beneficial effects of the anti-oestrogentamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies","volume":"62","author":"Z. Sthoeger","year":"2003","journal-title":"Ann. Rheum. Dis"},{"key":"67","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.4049\/jimmunol.175.3.1415","article-title":"Tamoxifen blocks estrogen-induced B cell maturation but not survival","volume":"175","author":"E. Peeva","year":"2005","journal-title":"J. Immunol"},{"key":"68","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1080\/08916934.2002.11873700","article-title":"Effects of oestradiol and the oestrogen antagonist Ici 182,780 on the delayed type hypersensitivity (DTH) index and on serum levels of IgM and IgG in ovariectomisedBalb\/C and MRL\/Mp-Lpr\/Lpr mice, a model of systemic lupus erythematosus (SLE)","volume":"33","author":"Y. Dhaher","year":"2001","journal-title":"Autoimmunity"},{"key":"69","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.4049\/jimmunol.172.3.1426","article-title":"Estrogen preferentially promotes the differentiation of CD11c+ CD11b(intermediate) dendritic cells from bone marrow precursors","volume":"172","author":"V. Paharkova-Vatchkova","year":"2004","journal-title":"J. Immunol"},{"key":"70","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1124\/mol.106.029629","article-title":"Estrogen receptor antagonist fulvestrant (ICI 182,780) inhibits the anti-inflammatory effect of glucocorticoids","volume":"71","author":"S. Cuzzocrea","year":"2007","journal-title":"Mol. Pharmacol"},{"key":"71","first-page":"797","article-title":"Fulvestrant (Faslodex), an estrogen selective receptor downregulator, in therapy of women with systemic lupus erythematosus. Clinical, serologic, bone density, and T cell activation marker studies: a double-blind placebo-controlled trial","volume":"35","author":"N. Abdou","year":"2008","journal-title":"J. Rheumatol"},{"key":"72","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.intimp.2007.10.011","article-title":"Leuprolide\u2014a GnRH agonist\u2014prevents restraint stress-induced immunosuppression via sex steroid-independent peripheral mechanism in mice","volume":"8","author":"S. Umathe","year":"2008","journal-title":"Int. Immunopharmacol"},{"key":"73","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.4049\/?jimmunol.0801458","article-title":"Luteinizing hormone-releasing hormone enhances T cell recovery following allogeneic bone marrow transplantation","volume":"182","author":"G. Goldberg","year":"2009","journal-title":"J. Immunol"},{"key":"74","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1080\/0962935031000134842","article-title":"The involvement of T lymphocytes in the pathogenesis of endometriotic tissues overgrowth in women with endometriosis","volume":"12","author":"K. Szyllo","year":"2003","journal-title":"Mediators Inflamm"},{"key":"75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/j.1600-0897.1995.tb00891.x","article-title":"Gonadotropin releasing hormone (GnRH) agonist induces down-regulation of the CD3+ CD25+ lymphocyte subpopulation in peripheral blood","volume":"33","author":"H. Ho","year":"1995","journal-title":"Am. J. Reprod. Immunol"},{"key":"76","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1159\/000010137","article-title":"Increased natural killer cell activities in patients treated with gonadotropin releasing hormone agonist","volume":"48","author":"N. Umesaki","year":"1999","journal-title":"Gynecol. Obstet. Invest"},{"key":"77","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/0029-7844(96)00146-9","article-title":"Natural cytotoxicity and GnRH agonist administration in advanced endometriosis: positive modulation on natural killer activity","volume":"88","author":"G. Garzetti","year":"1996","journal-title":"Obstet. Gynecol"},{"key":"78","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1023\/A:1006379925343","article-title":"Association between immunity and prognostic factors in early stage breast cancer patients before adjuvant treatment","volume":"59","author":"M. Sabbioni","year":"2000","journal-title":"Breast Cancer Res. Treat"},{"key":"79","first-page":"105","article-title":"T-lymphocytes in breast cancer: association with prognostic factors and response to treatment","volume":"39","author":"A. Ray","year":"2003","journal-title":"Ann. Natl. Acad. Med. Sci"},{"key":"80","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1472-6750-7-70","article-title":"Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells","volume":"7","author":"E. Pavoni","year":"2007","journal-title":"BMC. Biotechnol"},{"key":"81","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1073\/pnas.1108781108","article-title":"Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling","volume":"109","author":"V. Kristensen","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"82","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1210\/me.2011-1302","article-title":"Mini review: Inflammation: An instigator of more aggressive estrogen receptor (ER) positive breast cancers","volume":"26","author":"S. Baumgarten","year":"2012","journal-title":"Mol. Endocrinol"},{"key":"83","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1146\/annurev-med-070909-182917","article-title":"Mechanisms of endocrine resistance in breast cancer","volume":"62","author":"C. Osborne","year":"2011","journal-title":"Annu. Rev. Med"},{"key":"84","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s10555-010-9252-1","article-title":"Obesity and breast cancer: status of leptin and adiponectin in pathological processes","volume":"29","author":"M. Grossmann","year":"2010","journal-title":"Cancer Metastasis Rev"},{"key":"85","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1007\/s10549-009-0560-5","article-title":"Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy","volume":"121","author":"H. Kim","year":"2010","journal-title":"Breast Cancer Res. Treat"}],"container-title":["Acta Pharmaceutica"],"original-title":[],"link":[{"URL":"http:\/\/content.sciendo.com\/view\/journals\/acph\/62\/2\/article-p141.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/view\/j\/acph.2012.62.issue-2\/v10007-012-0012-3\/v10007-012-0012-3.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T23:14:19Z","timestamp":1743635659000},"score":1,"resource":{"primary":{"URL":"https:\/\/content.sciendo.com\/doi\/10.2478\/v10007-012-0012-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,6,1]]},"references-count":85,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.2478\/v10007-012-0012-3","relation":{},"ISSN":["1846-9558","1330-0075"],"issn-type":[{"type":"electronic","value":"1846-9558"},{"type":"print","value":"1330-0075"}],"subject":[],"published":{"date-parts":[[2012,6,1]]}}}